{{header
 | author     = 
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2013
 | month      = 07
 | day        = 18
 | notes      = ''{{USBill|113|S.|1323}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 1
 | title      = Protecting Our Youth from Dangerous Synthetic Drugs Act of 2013 ( S. 1323; 113th Congress)
 | bill       = 1323
 | billtype   = s
 | purpose    = To address the continued threat posed by dangerous synthetic drugs by amending the Controlled Substances Act relating to controlled substance analogues.
 | wikipedia  =
}}
      
{{Center|113th CONGRESS}}

 
{{Center|1st Session}}

 
{{Center|S. 1323}}

 
{{Center|IN THE SENATE OF THE UNITED STATES}}

  
{{Center|July 18, 2013}}

 
{{Center| 
[[w:|Mrs. Feinstein]] (for herself,
[[w:|Ms. Klobuchar]] ,
[[w:|Mr. Manchin]] , and
[[w:|Mr. Schumer]] ) introduced the following bill; which was read twice and referred to the [[w:United States Senate Committee on the Judiciary|Committee on the Judiciary]]  }}

  
{{Center|A BILL}}

 To address the continued threat posed by dangerous synthetic drugs by amending the Controlled Substances Act relating to controlled substance analogues.   

=Section 1. Short title=

This Act may be cited as the“ Protecting Our Youth from Dangerous Synthetic Drugs Act of 2013 ”. 

=Sec. 2. Enforcement=



==(a) In general– ==

The  Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/801 21 U.S.C. 801 et seq.] )is amended—
:(1) in section 102(32) , by striking subparagraph (A) and inserting the following:

<blockquote> 
::(A) Except as provided in subparagraph (C) , the term controlled substance analogue means—
:::(i) a substance whose chemical structure is substantially similar to the chemical structure of a controlled substance in schedule I or II—
::::(I) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II; or
::::(II) with respect to a particular person, which such person represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II; or
:::(ii) a substance designated as a controlled substance analogue by the [[w:|Controlled Substance Analogue Committee]] in accordance with section 201(i) . ; and 
</blockquote>

:(2) in section 201 , by adding at the end the following:

<blockquote> 
::(i) 
:::(1) The [[w:United States Department of Justice|Attorney General]] , in consultation with the [[w:Department of Health and Human Services|Secretary of Health and Human Services]] , shall establish an interagency committee, to be known as the [[w:|Controlled Substance Analogue Committee]] (referred to in this subsection as the“  [[w:|Committee]]  ”).
:::(2) The [[w:|Committee]] shall be—
::::(A) headed by the [[w:Drug Enforcement Administration|Administrator of the Drug Enforcement Administration]] ; and
::::(B) comprised of scientific experts in the fields of chemistry and pharmacology from—
:::::(i) the [[w:Drug Enforcement Administration|Drug Enforcement Administration]] ;
:::::(ii) the [[w:National Institutes of Health|National Institute on Drug Abuse]] ;
:::::(iii) the [[w:Centers for Disease Control and Prevention|Centers for Disease Control and Prevention]] ; and
:::::(iv) any other Federal agency determined by the [[w:United States Department of Justice|Attorney General]] , in consultation with the [[w:Department of Health and Human Services|Secretary of Health and Human Services]] , to be appropriate.
:::(3) 
::::(A) The [[w:|Committee]] shall convene, on an as needed basis, to establish and maintain a list of controlled substance analogues.
::::(B) A substance may be designated as a controlled substance analogue by the [[w:|Committee]] under this subsection if the substance is determined by the [[w:|Committee]] to be similar to a schedule I or II controlled substance in either its chemical structure or its predictive effect on the body, in such a manner as to make it likely that the substance will, or can be reasonably expected to have a potential for abuse.
::::(C) Evidence of human consumption by an individual or the public at large is not necessary before a substance may be designated as a controlled substance analogue under this subsection.
::::(D) The [[w:United States Department of Justice|Attorney General]] shall, through rulemaking, establish procedures of operation for the [[w:|Committee]] .
:::(4) 
::::(A) Not later than 30 days before each meeting of the [[w:|Committee]] , the [[w:United States Department of Justice|Attorney General]] shall submit to the [[w:Department of Health and Human Services|Secretary of Health and Human Services]] a notice of the meeting of the [[w:|Committee]] , which shall include—
:::::(i) a list of the substances to be considered by the [[w:|Committee]] during the meeting for designation as a controlled substance analogue; and
:::::(ii) a request for the [[w:Department of Health and Human Services|Secretary of Health and Human Services]] to make a determination of whether an exemption or approval for each substance listed under clause (i) is in effect under  section 505 of the Federal Food, Drug, and Cosmetic Act ( [http://www.law.cornell.edu/uscode/text/21/355 21 U.S.C. 355] ).
::::(B) Not later than 30 days after the date on which the [[w:Department of Health and Human Services|Secretary of Health and Human Services]] receives notice under subparagraph (A) , the [[w:Department of Health and Human Services|Secretary]] shall submit to the [[w:United States Department of Justice|Attorney General]] a written response to the request described under subparagraph (A)(ii) . The [[w:|Committee]] shall consider the response submitted by the [[w:Department of Health and Human Services|Secretary of Health and Human Services]] in determining whether to designate a substance considered by the [[w:|Committee]] at the meeting as a controlled substance analogue.
:::(5) 
::::(A) The [[w:United States Department of Justice|Attorney General]] shall publish in the Federal Register any designation made by the [[w:|Committee]] under this subsection.
::::(B) The [[w:Drug Enforcement Administration|Administrator of the Drug Enforcement Administration]] shall publish, on the website of the Drug Enforcement Administration, a description of each designation made by the [[w:|Committee]] under this subsection, which shall include—
:::::(i) the chemical and common name of the controlled substance analogue;
:::::(ii) the effective date of the determination, as described in paragraph (6)(A) ; and
:::::(iii) any schedule I or II controlled substance that the [[w:|Committee]] has determined a substance is an analogue of.
:::(6) A designation made by the [[w:|Committee]] under this subsection shall take effect on the date that is 30 days after the date on which the designation is published in the Federal Register under paragraph (5)(A) .
:::(7) If a substance designated as a controlled substance analogue by the [[w:|Committee]] under this section is subsequently scheduled through a rulemaking proceeding under subsection (a) , (d) , or (h) , the substance shall be automatically removed from the controlled substance analogue list.
:::(8) If a defendant challenges the designation of a controlled substance analogue made by the [[w:|Committee]] under this subsection the issue shall be considered a question of law. . 
</blockquote>


==(b) Funding– ==

  [[Public Law 102-395|Section 111(b)(2)(B) ofPublic Law 102–395 ]] ( [http://www.law.cornell.edu/uscode/text/21/886a 21 U.S.C. 886a(2)(B)] )is amended by inserting“controlled substance analogues,”after“substances,”. 

=Sec. 3. Importation of controlled substance analogues=

   Section 1002 of the Controlled Substances Import and Export Act ( [http://www.law.cornell.edu/uscode/text/21/952 21 U.S.C. 952] )is amended—
:(1) by redesignating subsections (c) through (e) as subsections (d) through (f) , respectively; and
:(2) by inserting after subsection (b) the following:

<blockquote> 
::(c) It shall be unlawful to import into the customs territory of the United States from any place outside thereof (but within the United States), or to import into the United States from any place outside thereof, any controlled substance analogue designated pursuant to  section 201(i) of the Controlled Substances Act ([http://www.law.cornell.edu/uscode/text/21/811 21 U.S.C. 811(i)])unless the controlled substance analogue is imported pursuant to such notification or declaration as the [[w:United States Department of Justice|Attorney General]] may by regulation prescribe. . 
</blockquote>
 

=Sec. 4. Directive to Sentencing Commission=



==(a) In general– ==

Pursuant to its authority under[http://www.law.cornell.edu/uscode/text/28/994  section 994of title 28, United States Code], the [[w:United States Sentencing Commission|United States Sentencing Commission]] shall review and, if appropriate, amend the Federal sentencing guidelines and policy statements to ensure the guidelines and policy statements provide adequate penalties for any offense involving the unlawful manufacturing, importing, exporting, or trafficking of controlled substance analogues under  part D of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/841 21 U.S.C. 841 et seq.] )or  part A of the Controlled Substances Import and Export Act ( [http://www.law.cornell.edu/uscode/text/21/951 21 U.S.C. 951 et seq.] )and similar offenses, including unlawful possession, possession with intent to commit any of the foregoing offenses, and attempt and conspiracy to commit any of the foregoing offenses.

==(b) Commission duties– ==

In carrying out this section, the [[w:United States Sentencing Commission|Sentencing Commission]] shall—
:(1) ensure that the sentences, guidelines, and policy statements relating to offenders convicted of these offenses are appropriately severe and reasonably consistent with other relevant directives and other Federal sentencing guidelines and policy statements;
:(2) make any necessary conforming changes to the Federal sentencing guidelines; and
:(3) assure that the guidelines adequately meet the purposes of sentencing as set forth in[http://www.law.cornell.edu/uscode/text/18/3553 section 3553(a)(2) of title 18, United States Code].  
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
